Mo1683 Computer-Aided Delineation of Early Neoplasia in Barrett's Esophagus Using High Definition Endoscopic Images

2013 ◽  
Vol 77 (5) ◽  
pp. AB471
Author(s):  
Erik J. Schoon ◽  
Fons Van Der Sommen ◽  
Svitlana Zinger ◽  
Peter H. De With
Endoscopy ◽  
2016 ◽  
Vol 48 (07) ◽  
pp. 617-624 ◽  
Author(s):  
Fons van der Sommen ◽  
Svitlana Zinger ◽  
Wouter Curvers ◽  
Raf Bisschops ◽  
Oliver Pech ◽  
...  

Endoscopy ◽  
2017 ◽  
Vol 49 (12) ◽  
pp. 1219-1228 ◽  
Author(s):  
Gideon Lipman ◽  
Raf Bisschops ◽  
Vinay Sehgal ◽  
Jacobo Ortiz-Fernández-Sordo ◽  
Rami Sweis ◽  
...  

Abstract Background and study aims Enhanced endoscopic imaging with chromoendoscopy may improve dysplasia recognition in patients undergoing assessment of Barrett’s esophagus (BE). This may reduce the need for random biopsies to detect more dysplasia. The aim of this study was to assess the effect of magnification endoscopy with I-SCAN (Pentax, Tokyo, Japan) and acetic acid (ACA) on dysplasia detection in BE using a novel mucosal and vascular classification system. Methods BE segments and suspicious lesions were recorded with high definition white-light and magnification endoscopy enhanced using all I-SCAN modes in combination. We created a novel mucosal and vascular classification system based on similar previously validated classifications for narrow-band imaging (NBI). A total of 27 videos were rated before and after ACA application. Following validation, a further 20 patients had their full endoscopies recorded and analyzed to model use of the system to detect dysplasia in a routine clinical scenario. Results The accuracy of the I-SCAN classification system for BE dysplasia improved with I-SCAN magnification from 69 % to 79 % post-ACA (P = 0.01). In the routine clinical scenario model in 20 new patients, accuracy of dysplasia detection increased from 76 % using a “pull-through” alone to 83 % when ACA and magnification endoscopy were combined (P = 0.047). Overall interobserver agreement between experts for dysplasia detection was substantial (0.69). Conclusions A new I-SCAN classification system for BE was validated against similar systems for NBI with similar outcomes. When used in combination with magnification and ACA, the classification detected BE dysplasia in clinical practice with good accuracy.Trials registered at ISRCTN (58235785).


2012 ◽  
Vol 75 (4) ◽  
pp. AB126 ◽  
Author(s):  
Enrico Grisan ◽  
Elisa Veronese ◽  
Giorgio Diamantis ◽  
Cristina Trovato ◽  
Cristiano Crosta ◽  
...  

Author(s):  
Hsin-Yu Fang ◽  
Stefan Stangl ◽  
Sabrina Marcazzan ◽  
Marcos J. Braz Carvalho ◽  
Theresa Baumeister ◽  
...  

Abstract Purpose The incidence of esophageal adenocarcinoma (EAC) has been increasing for decades without significant improvements in treatment. Barrett’s esophagus (BE) is best established risk factor for EAC, but current surveillance with random biopsies cannot predict progression to cancer in most BE patients due to the low sensitivity and specificity of high-definition white light endoscopy. Methods Here, we evaluated the membrane-bound highly specific Hsp70-specific contrast agent Tumor-Penetrating Peptide (Hsp70-TPP) in guided fluorescence molecular endoscopy biopsy. Results Hsp70 was significantly overexpressed as determined by IHC in dysplasia and EAC compared with non-dysplastic BE in patient samples (n = 12) and in high-grade dysplastic lesions in a transgenic (L2-IL1b) mouse model of BE. In time-lapse microscopy, Hsp70-TPP was rapidly taken up and internalized  by human BE dysplastic patient–derived organoids. Flexible fluorescence endoscopy of the BE mouse model allowed a specific detection of Hsp70-TPP-Cy5.5 that corresponded closely with the degree of dysplasia but not BE. Ex vivo application of Hsp70-TPP-Cy5.5 to freshly resected whole human EAC specimens revealed a high (> 4) tumor-to-background ratio and a specific detection of previously undetected tumor infiltrations. Conclusion In summary, these findings suggest that Hsp70-targeted imaging using fluorescently labeled TPP peptide may improve tumor surveillance in BE patients.


2021 ◽  
Vol 14 ◽  
pp. 263177452110499
Author(s):  
Rebecca Sullivan ◽  
Ramzi Mulki ◽  
Shajan Peter

Endoscopic eradication therapy for Barrett’s esophagus has been established as an effective management strategy for patients with Barrett’s esophagus with dysplasia and early esophageal cancer. Among the endoscopic therapies, ablation techniques such as radiofrequency ablation and cryoablation are effective primary treatment interventions with acceptable low complication rates forming the spectrum of a multimodal approach. Appropriate selection of patients, high-definition endoscopic evaluation, and dedicated histological assessment are important cornerstones to help navigate to the best effective treatment method. Carefully structured surveillance programs and preventive measures will be needed to provide long-term durability for maintaining complete remission.


Sign in / Sign up

Export Citation Format

Share Document